Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
New England Journal of Medicine2013Vol. 369(25), pp. 2379–2390
Citations Over TimeTop 1% of 2013 papers
Thorsten Klampfl, Heinz Gisslinger, Ashot S. Harutyunyan, Harini Nivarthi, Elisa Rumi, Jelena D. Milosevic Feenstra, Nicole C.C. Them, Tiina Berg, Bettina Gisslinger, Daniela Pietra, Doris Chen, Gregory I. Vladimer, Klaudia Bagienski, Chiara Milanesi, Ilaria Carola Casetti, Emanuela Sant’Antonio, Virginia Valeria Ferretti, Chiara Elena, Fiorella Schischlik, Ciara Cleary, Melanie Six, Martin Schalling, Andreas Schönegger, Christoph Bock, Luca Malcovati, Cristiana Pascutto, Giulio Superti‐Furga, Mario Cazzola, Róbert Královics
Abstract
Most patients with essential thrombocythemia or primary myelofibrosis that was not associated with a JAK2 or MPL alteration carried a somatic mutation in CALR. The clinical course in these patients was more indolent than that in patients with the JAK2 V617F mutation. (Funded by the MPN Research Foundation and Associazione Italiana per la Ricerca sul Cancro.).
Related Papers
- → Calreticulin Exon 9 Mutations in Myeloproliferative Neoplasms(2014)38 cited
- → Frequency of Calreticulin (CALR) Mutation and Its Clinical Prognostic Significance in Essential Thrombocythemia and Primary Myelofibrosis: A Meta-analysis(2016)9 cited
- → Calreticulin and JAK2V617F Mutations in Essential Thrombocythemia and Their Potential Role in Diagnosis and Prognosis(2015)1 cited
- → JAK2 V617F positive mutation transformed to calreticulin mutation in one patient with essential thrombocythemia(2017)
- → Faculty Opinions recommendation of Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.(2016)